JP2015535274A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535274A5
JP2015535274A5 JP2015540222A JP2015540222A JP2015535274A5 JP 2015535274 A5 JP2015535274 A5 JP 2015535274A5 JP 2015540222 A JP2015540222 A JP 2015540222A JP 2015540222 A JP2015540222 A JP 2015540222A JP 2015535274 A5 JP2015535274 A5 JP 2015535274A5
Authority
JP
Japan
Prior art keywords
acid
tapentadol
ester
base
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535274A (ja
JP6360488B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/056082 external-priority patent/WO2014068372A1/en
Publication of JP2015535274A publication Critical patent/JP2015535274A/ja
Publication of JP2015535274A5 publication Critical patent/JP2015535274A5/ja
Application granted granted Critical
Publication of JP6360488B2 publication Critical patent/JP6360488B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540222A 2012-11-01 2012-11-01 非経口投与のためのタペンタドールの薬学的組成物 Expired - Fee Related JP6360488B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/056082 WO2014068372A1 (en) 2012-11-01 2012-11-01 Pharmaceutical composition of tapentadol for parenteral administration

Publications (3)

Publication Number Publication Date
JP2015535274A JP2015535274A (ja) 2015-12-10
JP2015535274A5 true JP2015535274A5 (OSRAM) 2018-06-14
JP6360488B2 JP6360488B2 (ja) 2018-07-18

Family

ID=47297340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540222A Expired - Fee Related JP6360488B2 (ja) 2012-11-01 2012-11-01 非経口投与のためのタペンタドールの薬学的組成物

Country Status (7)

Country Link
US (1) US9629818B2 (OSRAM)
EP (1) EP2914243A1 (OSRAM)
JP (1) JP6360488B2 (OSRAM)
KR (1) KR20150075408A (OSRAM)
BR (1) BR112015009839A2 (OSRAM)
CA (1) CA2890270A1 (OSRAM)
WO (1) WO2014068372A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20170290771A1 (en) * 2016-04-12 2017-10-12 Southern Research Institute Biodegradable in situ forming microparticles and methods for producing the same
WO2018055070A1 (en) * 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス, インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー
US12364792B2 (en) 2018-01-08 2025-07-22 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
WO2019221853A1 (en) 2018-05-12 2019-11-21 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
CA2735857C (en) * 2008-09-05 2019-05-28 Petra Bloms-Funke Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
CA2757757C (en) * 2009-04-30 2017-10-24 Ulrich Jahnel Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
AU2010264670A1 (en) * 2009-06-24 2012-01-19 Merck Sharp & Dohme B.V. Injectable formulations containing asenapine and method of treatment using same
US8288592B2 (en) * 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2011107876A2 (en) * 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011139595A2 (en) * 2010-04-27 2011-11-10 Medtronic, Inc. Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
ES3035088T3 (en) 2010-07-23 2025-08-28 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR101903351B1 (ko) * 2011-03-04 2018-10-04 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여

Similar Documents

Publication Publication Date Title
JP2015535274A5 (OSRAM)
JP5728128B2 (ja) リスペリドン徐放性ミクロスフェア組成物
US12527737B2 (en) Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
US20140243278A1 (en) Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
JP6249944B2 (ja) 注射製剤
JP6360488B2 (ja) 非経口投与のためのタペンタドールの薬学的組成物
WO2010118639A1 (zh) 氨氯地平微球制剂、其制备方法及应用
JP4551988B2 (ja) 2−メチル−チエノ−ベンゾジアゼピン製剤
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
JP2014501781A5 (OSRAM)
KR20190005183A (ko) 풀베스트란트 제제 및 그의 사용 방법
Bhowmik et al. Solid dispersion-a approach to enhance the dissolution rate of poorly water soluble drugs
WO2012026896A1 (en) Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
JP6772255B2 (ja) 延長された有効期間を有するアリピプラゾール注射用懸濁製剤
TW202216150A (zh) 包含p2y12受體拮抗劑的水性醫藥組合物
JP6120876B2 (ja) Hiv吸着阻害剤のプロドラッグ化合物と賦形剤の共処理方法および製剤
AU2018354431A1 (en) Dosage regimen of paliperidone palmitate extended-release injectable suspension
WO2017195897A1 (ja) 経皮製剤
JP2009545564A (ja) 長時間にわたって活性本体を放出する皮下移植物
CN106265524A (zh) 盐酸沙拉沙星固体分散制剂及其制备方法
CN1353610A (zh) 口服用药物组合物
WO2011148253A2 (en) Solid dosage forms of antipsychotics
JPWO2000078318A1 (ja) 経口用医薬組成物